^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Erleada (apalutamide) (Androgen receptor antagonist) + imaradenant (AZD4635) (Adenosine A2A receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting CD73 augments the efficacy of A2aR blockade in PTEN-deficient prostate cancer
Published date:
03/09/2022
Excerpt:
The efficacy of AZD4635 versus aCD73 plus AZD4635 was evaluated in an in vivo castration-sensitive model of Pten-null prostate cancer treated with apalutamide...In this model, mice were treated for eight weeks to allow for the progression to castration-resistant prostate cancer (CRPC) and in this setting, the treatment combination of aCD73/AZD4635 improved tumor burden reduction to 34.3% from 23.1% in AZD4635 treated mice...
Source:
Title:
Abstract 1071: Targeting A2aR in mouse Pten-deficient prostate cancer
Published date:
05/15/2020
Excerpt:
For the CSPC/CRPC models, mice were orchidectomized and treated with apalutamide with or without AZD4635 for four or eight weeks to represent CSPC or CRPC phenotypes, respectively. In these settings, treatment with AZD4635 improved the reduction of tumor burden by 16.4% (P=0.165) and 16.8% (P=0.123) in CSPC and CRPC, respectively.
DOI:
10.1158/1538-7445.AM2020-1071
